You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

MS drugs from Biogen Idec, Genzyme get recommendations from European panel

Analysts say Tecfidera could add sales of $6 billion by 2020 for Biogen Idec.

Essdras M Suarez/Boston Globe file

Analysts say Tecfidera could add sales of $6 billion by 2020 for Biogen Idec.

Biogen Idec has won support from a European panel for Tecfidera, a pill to treat multiple sclerosis.

A Weston company known for such MS drugs as Avonex and Tysabri, Biogen Idec said it has received a positive opinion on Tecfidera from the Committee for Medicinal Products for Human Use, which is recommending that European Union regulators approve the drug as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis.

Continue reading below

A decision on Tecfidera by the US Food and Drug Administration is expected shortly.

“We believe Tecfidera will raise expectations for what people living with MS can achieve with their therapy,” Biogen Idec chief executive George Scangos said in a statement.

Earlier this week, Biogen Idec announced that the US Patent Office had granted it broad protection for Tecfidera.

Avonex is typically injected once a week. Tysabi is generally taken by infusion once a month. And Tecfidera is envisioned as a capsule taken twice a day.

Biogen’s stock closed Friday at $178, up almost one percent.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week